Storage and handling
Other information some users may experience a brief tingling sensation store at 15 o to 25 o C (59 o to 77 o F)
Other information some users may experience a brief tingling sensation store at 15 o to 25 o C (59 o to 77 o F)
Active ingredients Purpose
Glycerin 0.2%..................................................................................Lubricant
Hypromellose 0.2%..........................................................................Lubricant
Polyethylene glycol 400 1%..............................................................Lubricant
Uses
Warnings
For external use only.
Do not use:
When using this product
Stop use and ask a doctor if
If pregnant or breast-feeding,
ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or
contact a Poison Control Center right away
Other information
Inactive ingredients
benzalkonium chloride, boric acid, dextrose, glycine, magnesium chloride,
potassium chloride, purified water, sodium borate, sodium chloride, sodium
citrate, sodium lactate.
Distributed by C.D.M.A., Inc.
43157 W. Nine Mile
Novi, MI 48376-0995
Made in Korea
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 259581 | glycerin 0.2 % / hypromellose 0.2 % / polyethylene glycol 400 1 % Ophthalmic Solution | PSN | 3 |
| 259581 | glycerin 2 MG/ML / hypromellose 2 MG/ML / polyethylene glycol 400 10 MG/ML Ophthalmic Solution | SCD | 3 |
| 259581 | glycerin 0.2 % / hypromellose 0.2 % / PEG 400 1 % Ophthalmic Solution | SY | 3 |
| Class | Version | Type | Effective |
|---|---|---|---|
| GLYCERIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 63868-967-15 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-eb5a-f424-e053-dadaa90a57ce | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63868-967-15 | QUALITY CHOICE LUBRICANT TEARS EYE | 1 in 1 CARTON | SOLUTION/ DROPS | 1 | 3 | |
| 63868-967-15 | QUALITY CHOICE LUBRICANT TEARS EYE | 15 mL in 1 BOTTLE | SOLUTION/ DROPS | 15 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63868-967 | QUALITY CHOICE LUBRICANT TEARS EYE (GLYCERIN, HYPROMELLOSE, POLYETHYLENE GLYCOL 400) SOLUTION/ DROPS [CHAIN DRUG MARKETING ASSOCIATION INC] | 3 | Legacy NDC, 2 package rows | 20121013_ac9fb8ee-d0b9-43dc-900b-1362b56974cc.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| GLYCERIN | ACTIVE INGREDIENT | PDC6A3C0OX | 3 | |
| HYPROMELLOSES | ACTIVE INGREDIENT | 3NXW29V3WO | 3 | |
| POLYETHYLENE GLYCOL 400 | ACTIVE INGREDIENT | B697894SGQ | 3 | |
| GLYCERIN | ACTIVE MOIETY | PDC6A3C0OX | 3 | |
| HYPROMELLOSES | ACTIVE MOIETY | 3NXW29V3WO | 3 | |
| POLYETHYLENE GLYCOL 400 | ACTIVE MOIETY | B697894SGQ | 3 | |
| BENZALKONIUM CHLORIDE | INACTIVE INGREDIENT | F5UM2KM3W7 | 3 | |
| BORIC ACID | INACTIVE INGREDIENT | R57ZHV85D4 | 3 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 3 | |
| POTASSIUM CHLORIDE | INACTIVE INGREDIENT | 660YQ98I10 | 3 | |
| SODIUM BORATE | INACTIVE INGREDIENT | 91MBZ8H3QO | 3 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 63868-967 | 63868-967-15 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| GLYCERIN | PDC6A3C0OX | ACTIB |
| HYPROMELLOSES | 3NXW29V3WO | ACTIB |
| POLYETHYLENE GLYCOL 400 | B697894SGQ | ACTIB |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| BORIC ACID | R57ZHV85D4 | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| SODIUM BORATE | 91MBZ8H3QO | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYSTEM / IONTOPHORESIS | 3.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | ENEMA / RECTAL | 0.7 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | LIQUID / NASAL | 2 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, DELAYED RELEASE / ORAL | 100 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | OINTMENT / TOPICAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ORAL | 98 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVENOUS | 10 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBMUCOSAL | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, EXTENDED RELEASE / ORAL | 335.1 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SUSPENSION/ DROPS / AURICULAR (OTIC) | 3 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / DENTAL | 0.4 %w/v | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SOLUTION / TOPICAL | 0.02 %w/v | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SHAMPOO / TOPICAL | 2 %w/w | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | CAPSULE / ORAL | 62 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAMUSCULAR | 1486 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ORAL | 1126 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, DELAYED RELEASE / ORAL | 97 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | EMULSION / OPHTHALMIC | 0.3 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBCUTANEOUS | 1486 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SUSPENSION / OPHTHALMIC | 0.03 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRAVESICAL | 351 mg | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | CREAM / TOPICAL | NA | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / EPIDURAL | 0.9 %w/v | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SUSPENSION / ORAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 0.68 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / SUBARACHNOID | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | EMULSION / TOPICAL | 1.3 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | ELIXIR / ORAL | 1.3 mg/5ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | ENEMA / RECTAL | 60 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | IMPLANT / SUBCUTANEOUS | 77 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SYRUP / ORAL | 40 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION / INTRAVENOUS | 1 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION/ DROPS / OPHTHALMIC | 0.13 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / INTRAMUSCULAR | 9 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / INTRA-ARTICULAR | 45 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / AURICULAR (OTIC) | 0.01 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PERIDURAL | 8.07 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | SUSPENSION / AURICULAR (OTIC) | 0.6 %w/v | ||
| SODIUM BORATE | SODIUM BORATE | 91MBZ8H3QO | EMULSION / OPHTHALMIC | 0.11 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVENOUS | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| BORIC ACID | BORIC ACID | R57ZHV85D4 | INJECTION, SOLUTION / INTRAVENOUS | 210 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | TABLET / ORAL | 231 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION / INTRAOCULAR | 38 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL | 1.35 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / ENDOTRACHEAL | 68 mg | ||
| BENZALKONIUM CHLORIDE | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | SUSPENSION/ DROPS / TOPICAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRADERMAL | 7 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION, SOLUTION / INTRAVENOUS | 330 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| eadfb65d-e5e5-4913-a411-205b9587310d | ac9fb8ee-d0b9-43dc-900b-1362b56974cc | 2012-09-30 | Warnings | eadfb65d-e5e5-4913-a411-205b9587310d ac9fb8ee-d0b9-43dc-900b-1362b56974cc |
Adverse event summaries are temporarily unavailable. Other product information remains available.